Back to News
Market Impact: 0.2
Roth Capital Initiates Coverage of Nautilus Biotechnology with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Roth Capital initiated coverage of Nautilus Biotechnology (NASDAQ: NAUT) with a Buy rating on September 29, 2026. NAUT closed at $1.36 that day; the article does not provide a price target or complete prior-close comparison.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
NAUT0.55
More News
- Why is Lynas Rare Earths stock sliding today?
- Micron capacity buildout: These equipment suppliers stand to benefit
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- These two chip stocks could join the elite $2 trillion tech giant club, says top analyst
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund